The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. حسب Zahra Hosseininia (22265113)

The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. حسب Shuhuan Zhang (748003)

HSF2 reduced the decrease in the MMP in Caco-2 cells, which were observed by laser confocal microscopy. حسب Wen Wang (6570)

"…Red fluorescence indicated that there was no obvious abnormality in the MMP, while green fluorescence represented a decrease in the MMP. B: Statistical bar chart of the ratio of red to green fluorescence, <i>P</i> value of less than 0.05 was identified as* and <i>P</i> value of less than 0.01 was identified as**. …"

Line graph showing the increase or decrease in the average number of bee swarms caught over the past three years (Mean  حسب Beatrice T. Nganso (4114768)

ECoG timescales decrease during spatial attention. حسب Isabel Raposo (21615517)

"…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …"

Incorporating a social responsibility goal in the prompt causes overleverage in utilities (A) and decreases risk of low ESG rating (B) (Study 3). حسب Philipp Winder (21615570)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. حسب Ryan J. Treves (13527735)

Data Sheet 1_Emotional prompting amplifies disinformation generation in AI large language models.docx حسب Rasita Vinay (21006911)

"…Introduction<p>The emergence of artificial intelligence (AI) large language models (LLMs), which can produce text that closely resembles human-written content, presents both opportunities and risks. …"

GPT-4 results in decreased error rate for all tasks with increasing complexity when compared to GPT-3.5-turbo. حسب Jacqueline A. Jansen (14894276)

Feasibility of AI-powered assessment scoring: Can large language models replace human raters? حسب Michael Jaworski III (22156096)

"…<p><b>Objective:</b> To assess the feasibility, accuracy, and reliability of using ChatGPT-4.5 (early-access), a large language model (LLM), for automated scoring of Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) protocols. …"

<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" حسب Kira Shaw (18796168)

"…<p dir="ltr">The CSV file 'Eyreetal_DrainingVein_SourceData' contains the averaged time series traces and extracted metrics from individual experiments used across Figures 1-5 in the manuscript "Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins". The following acronyms included in the CSV file are defined as follows: Hbt is total hemoglobin, Art is artery region, DV is draining vein region, WV is whisker vein region, SEM is standard error mean, TS is time series, max peak is maximum peak, min peak is minima, AUC is area under the curve, WT is wild-type, AD is Alzheimer's disease, ATH is atherosclerosis and MIX is mixed AD/atherosclerosis. …"

NSC population and proliferation decrease drastically during the second postnatal week of DG development. حسب Cristina Medina-Menéndez (21800157)

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)